<DOC>
	<DOCNO>NCT00514033</DOCNO>
	<brief_summary>Following licensing PoliorixTM Korea , study collect safety data routine use vaccine 600 child accord regulation Korean Food Drugs Administration ( KFDA ) .</brief_summary>
	<brief_title>A Post-marketing Safety Study GSK Bio IPV Vaccine ( PoliorixTM ) Korean Children</brief_title>
	<detailed_description>An open , multicentric , post-marketing surveillance study monitor safety reactogenicity GlaxoSmithKline Biologicals . Poliomyelitis vaccine ( inactivate ) -PoliorixTM. , administer Korean child primary vaccination healthy subject age two six month booster vaccination subject age four six year .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A healthy male female child two six month age ( primary vaccination ) four six year age ( booster vaccination ) time vaccination . Subjects investigator believe parents/guardians comply requirement protocol ( e.g . completion diary card ) Written informed consent obtain parent/ guardian subject At time study entry , contraindication precaution use indicated Korean Label check subject must include study contraindication risk</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>